{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:43:34Z","timestamp":1761101014854,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":2109,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.bbmt.2009.03.020","type":"journal-article","created":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T04:43:33Z","timestamp":1245213813000},"page":"881-885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Sirolimus as Primary Treatment of Acute Graft-versus-Host Disease following Allogeneic Hematopoietic Cell\u00a0Transplantation"],"prefix":"10.1016","volume":"15","author":[{"given":"Joseph","family":"Pidala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jongphil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Anasetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2009.03.020_bib1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/bbmt.2002.v8.pm12171485","article-title":"Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems","volume":"8","author":"MacMillan","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2009.03.020_bib2","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/blood.V80.12.2964.2964","article-title":"Cytokine dysregulation and acute graft-versus-host disease","volume":"80","author":"Antin","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2009.03.020_bib3","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.V95.9.2754.009k25_2754_2759","article-title":"The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation","volume":"95","author":"Hill","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2009.03.020_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/j.seminhematol.2005.09.007","article-title":"Prophylaxis and treatment of acute graft-versus-host disease","volume":"43","author":"Chao","year":"2006","journal-title":"Semin Hematol"},{"key":"10.1016\/j.bbmt.2009.03.020_bib5","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.V75.4.1024.1024","article-title":"Treatment of moderate\/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk factors and outcome","volume":"75","author":"Weisdorf","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2009.03.020_bib6","first-page":"2303","article-title":"Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation","volume":"92","author":"Ratanatharathorn","year":"1998","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bbmt.2009.03.020_bib7","first-page":"2062","article-title":"Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors","volume":"96","author":"Nash","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2009.03.020_bib8","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood.V76.8.1464.1464","article-title":"A retrospective analysis of therapy for acute graft-versus-host disease:Initial treatment","volume":"76","author":"Martin","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2009.03.020_bib9","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2004-03-0854","article-title":"Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial","volume":"104","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2009.03.020_bib10","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1182\/blood-2007-09-112987","article-title":"Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease","volume":"111","author":"Levine","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2009.03.020_bib11","article-title":"BMT CTN 0302: A phase II randomized trial evaluating etanercept, mycophenolate mofetil (MMF), denileukin diftitox, and pentostatin in combination with corticosteroids in 180 patients (pts) with newly diagnosed acute graft vs. host disease (aGVHD)","author":"Alousi","year":"2008","journal-title":"Presented at American Society of Hematology meeting"},{"key":"10.1016\/j.bbmt.2009.03.020_bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4161\/cbt.2.3.360","article-title":"Rapamycins: mechanism of action and cellular resistance","volume":"2","author":"Huang","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.bbmt.2009.03.020_bib13","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1073\/pnas.121145898","article-title":"The target of rapamycin (TOR) proteins","volume":"98","author":"Raught","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2009.03.020_bib14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1182\/blood-2005-07-3032","article-title":"Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells","volume":"107","author":"Coenen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2009.03.020_bib15","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/sj.onc.1207542","article-title":"Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression","volume":"23","author":"Fingar","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bbmt.2009.03.020_bib16","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood-2006-09-046219","article-title":"Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation","volume":"109","author":"Cutler","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2009.03.020_bib17","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.bbmt.2008.05.024","article-title":"Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation","volume":"14","author":"Alyea","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2009.03.020_bib18","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1097\/00007890-200112270-00010","article-title":"Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease","volume":"72","author":"Benito","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2009.03.020_bib19","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2009.03.020_bib20","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2009.03.020_bib21","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1200\/JCO.2008.17.7279","article-title":"Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning","volume":"26","author":"Armand","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2009.03.020_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bbmt.2007.07.016","article-title":"A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2009.03.020_bib23","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1200\/JCO.2004.01.103","article-title":"Putting the rap on Akt","volume":"22","author":"Thompson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2009.03.020_bib24","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway","volume":"296","author":"Cantley","year":"2002","journal-title":"Science"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879109001712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879109001712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:34:32Z","timestamp":1761057272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879109001712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S1083879109001712"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2009.03.020","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sirolimus as Primary Treatment of Acute Graft-versus-Host Disease following Allogeneic Hematopoietic Cell\u00a0Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2009.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}